- TSX.V: DXD
- OTCQB: TDSGF FSE: 3D0
Stock Information (as of November 23, 2018)
|Issued and Outstanding Shares||64,531,545|
|Fully Diluted Shares||83,934,795|
1. BREAKTHROUGH TECHNOLOGY
Proprietary TeloView™ software algorithms could represent a major medical advancement in patient diagnosis, treatment and the development of companion diagnostics in precision medicine.
Structural biomarker based on 3D telomere organization.
2. VALIDATION IN 2018
Completion of HL clinical trial and validation of Telo-HL™ test will introduce 1st in class 3D telomere biomarker to diagnostic market.
External validation is expanding through PoC studies in PC, LC, MM.
3. TELOVIEW™ IS A PLATFORM
20 cancers + Alzheimer’s disease have all tested positively in 25+ clinical studies.
Platform is agnostic to the underlying mutations and acts as a universal marker of genomic instability.
4. EXPERT TEAM
Accomplished leadership and scientific team with ability to develop and commercialize platform and secure strategic partners.
World-class Scientific and Business advisors supporting 3DS.
5. SCALABLE BUSINESS MODEL
Tests can be commercialized as LDT’s in NA and CE in EU.
Option to partner with industry majors through licensing agreements. Pharma services and CDx opportunities in discussion.
6. FISCAL MANAGEMENT
Driving growth through strategic allocation of capital.
Controlling expenses through streamlined operations and tight fiscal management.